Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Rivervest Venture Partners
BioCentury | Jan 31, 2025
Finance
Versant, Orbimed lead $65M launch of GIP-focused start-up Helicore
In BioCentury’s Venture Report: Oncomatryx, Quibin raise cash in Spain; Atalanta draws $97M; Forbion’s BioEconomy Fund
BioCentury | May 9, 2024
Finance
Venture report: Big rounds for Bluejay, Attovia and Zenas
Strong fundraising week also included launches by Prologue and Commit, plus raises by Aardvark, Memo and OverT
BioCentury | Mar 21, 2024
Finance
Venture report: Mirador’s $400M launch; megarounds for Clasp, Capstan, Engrail
Arch backs immunology/fibrosis start-up; JHU spinout launches with $150M; San Diego-based pair advance clinical plans in oncology and neuroscience
BioCentury | Dec 16, 2023
Management Tracks
Mistras, Martin join Viatris
Plus: Nassim Usman at the helm at Totus as it raises $66M series B round, and updates from Tourmaline, HKEX, CIRM, CorMedix and RiverVest
BioCentury | Sep 28, 2023
Deals
Sept. 27 Quick Takes: Roche and Ionis taking another approach to Huntington disease
Plus: Venture financings for Avalyn, Sitryx and Singaporean newco Automera and updates from Biohaven, Ginkgo, Pfizer, Gilead and Gracell
BioCentury | Jan 14, 2023
Finance
Jan. 13 Quick Takes: Stevens’ Structure Therapeutics files for IPO
Plus: Expanded label for Novo’s Rybelsus and updates from China Resources, LinusBio, MPC Therapeutics, Sabin and more
BioCentury | Nov 15, 2022
Finance
Nov. 15 Quick Takes: Panacea to deploy $276M in pair of funds
Plus: Acrivon’s IPO; fundings for Bonum, CG Oncology and Jnana; and pipeline updates from Arcutis and Everest
BioCentury | Aug 17, 2022
Regulation
Aug. 16 Quick Takes: Everest extends runway by offloading Trodelvy
Plus Flagship’s Senda raises $123M and updates from Bluejay, AZ, Ventyx and more
BioCentury | Aug 12, 2021
Emerging Company Profile
Bluejay: combining HBV therapies to reach a functional cure
Emerging Company Profile: Led by Keting Chu, Bluejay is advancing HBV assets in-licensed from Novartis
BioCentury | Jul 15, 2021
Finance
Wugen secures $172M series B to advance memory NK, CAR T cell therapies
Financing to support clinical studies of multiple allogeneic programs
Items per page:
1 - 10 of 101